TNFRSF8 and classic Hodgkin lymphoma: The activity of anti‐CD30 CAR‐T cells has been so far modest, and attempts should be made to modify them structurally, with the aim to improve the anti‐tumor activity and also to antagonize the immunosuppressive microenvironment of cHL.